Anticorps Polyclonal de lapin anti-DROSHA

• Phare
• Validé par KD/KO

DROSHA Polyclonal Antibody for WB, IF/ICC, ELISA

Hôte / Isotype

Lapin / IgG

Réactivité testée

Humain

Applications

WB, IF/ICC, ELISA

Conjugaison

Non conjugué

Publications(1)

Avis (1)

N° de cat : 27958-1-AP

Synonymes

RNASEN, EC:3.1.26.3, ETOHI2, HSA242976, p241

---

Galerie de données de validation

• 

  WB analysis using 27958-1-AP

  Various lysates were subjected to SDS PAGE followed by western blot with 27958-1-AP (DROSHA antibody) at dilution of 1:8000 incubated at room temperature for 1.5 hours.

• 

  WB analysis of HEK-293 using 27958-1-AP

  WB result of DROSHA antibody (27958-1-AP; 1:6000; incubated at room temperature for 1.5 hours) with sh-Control and sh-DROSHA transfected HEK-293 cells.

• 

  IF Staining of U2OS using 27958-1-AP

  Immunofluorescent analysis of (4% PFA) fixed U2OS cells using DROSHA antibody (27958-1-AP) at dilution of 1:200 and CoraLite®488-Conjugated AffiniPure Goat Anti-Rabbit IgG(H+L), CL594-Phalloidin (red).

• 

  IF Staining of U2OS using 27958-1-AP

  Immunofluorescent analysis of (4% PFA) fixed U2OS cells using DROSHA antibody (27958-1-AP) at dilution of 1:400 and CoraLite®488-Conjugated AffiniPure Goat Anti-Rabbit IgG(H+L), CL594-phalloidin (red).

---

Applications testées

• Résultats positifs en WB: cellules HEK-293T, cellules HEK-293, cellules HeLa
• Résultats positifs en IF/ICC: cellules U2OS,

Dilution recommandée

• Western Blot (WB): WB : 1:2000-1:16000
• Immunofluorescence (IF)/ICC: IF/ICC : 1:50-1:500

It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Sample-dependent, check data in validation data gallery

Applications publiées

• WB: See 1 publications below

Informations sur le produit

27958-1-AP cible DROSHA dans les applications de WB, IF/ICC, ELISA et montre une réactivité avec des échantillons Humain

• Réactivité: Humain
• Réactivité citée: Humain
• Hôte / Isotype: Lapin / IgG
• Clonalité: Polyclonal
• Type: Anticorps
• Immunogène: DROSHA Protéine recombinante Ag27533
• Nom complet: ribonuclease type III, nuclear
• Masse moléculaire calculée: 159 aa
• Poids moléculaire observé: 150 kDa
• Numéro d’acquisition GenBank: NM_001100412
• Symbole du gène: DROSHA
• Identification du gène (NCBI): 29102
• Conjugaison: Non conjugué
• Forme: Liquide
• Méthode de purification: Purification par affinité contre l'antigène
• Tampon de stockage: PBS with 0.02% sodium azide and 50% glycerol
• Conditions de stockage: Stocker à -20°C. Stable pendant un an après l'expédition. L'aliquotage n'est pas nécessaire pour le stockage à -20^oC Les 20ul contiennent 0,1% de BSA.

Informations générales

DROSHA, also named as RN3, RNASE3L, P241 and RNASEN, is double-stranded (ds) RNA-specific endoribonuclease that is involved in the initial step of microRNA (miRNA) biogenesis. It is a component of the microprocessor complex that is required to process primary miRNA transcripts (pri-miRNAs) to release precursor miRNA (pre-miRNA) in the nucleus. Within the microprocessor complex, RNASEN/DROSHA cleaves the 3' and 5' strands of a stem-loop in pri-miRNAs (processing center 11 bp from the dsRNA-ssRNA junction) to release hairpin-shaped pre-miRNAs that are subsequently cut by the cytoplasmic DICER to generate mature miRNAs. RNASEN is involved also in pre-rRNA processing. Cleaves double-strand RNA and does not cleave single-strand RNA. And it is involved in the formation of GW bodies. The antibody is specific to DROSHA.

Publications

Species	Application	Title
human	WB	Cell Mol Life Sci; N4-acetylcytidine modifies primary microRNAs for processing in cancer cells; Authors - Hailong Zhang

Avis

The reviews below have been submitted by verified Proteintech customers who received an incentive for providing their feedback.

---

FH

Roy (Verified Customer) (06-15-2024)

Works very well to detect DROSHA by WB from HeLa extracts (1/1000 dilution, 1h incubation at room temperature).

• Applications: Western Blot
• Primary Antibody Dilution: 1/1000
• Cell Tissue Type: HeLa

{{ptg:RelatedPrimaryAntibodies}}